RxDoctor Payments Data

Ashley Corkill, APRN

Nurse Practitioner · Wichita, KSNPI 1740683911

Payments from drug & device makers

$2,744in general payments, 2019–2025

Across 21 payments — averaging $130.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$841
  • GSK$560
  • Inspire Medical Systems, Inc.$507
  • Sanofi$230
  • Merck$223
  • Pulmonx Corporation$170
  • plus $212 from 2 others

What the payments were for

  • Travel & lodging$50718%
  • Food & beverage$2,23782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,744 in reported general payments places this provider in the 85th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$68,095
Medicare patients
591
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter270$195,154
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$62,812
Spiriva RespimatTiotropium Bromide78$44,001
Breo ElliptaFluticasone/Vilanterol76$38,173
Ambrisentan12$26,611
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$20,553
EliquisApixaban28$16,396
SymbicortBudesonide/Formoterol Fumarate47$12,085
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,864
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate34$5,499
Combivent RespimatIpratropium/Albuterol Sulfate11$5,380
Albuterol Sulfate HfaAlbuterol Sulfate164$4,323
Ventolin HfaAlbuterol Sulfate58$3,579
Wixela InhubFluticasone Propion/Salmeterol17$2,923
Fluticasone Propionate HfaFluticasone Propionate12$2,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$560$243,191367 claims
AstraZenecaBreztri Aerosphere, Symbicort$841$74,897130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →